ProQR Therapeutics (PRQR) Income towards Parent Company (2021 - 2025)
Historic Income towards Parent Company for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$12.9 million.
- ProQR Therapeutics' Income towards Parent Company fell 3836.62% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year decrease of 8678.42%. This contributed to the annual value of -$30.0 million for FY2024, which is 120.94% up from last year.
- ProQR Therapeutics' Income towards Parent Company amounted to -$12.9 million in Q3 2025, which was down 3836.62% from -$14.6 million recorded in Q2 2025.
- ProQR Therapeutics' Income towards Parent Company's 5-year high stood at -$2.9 million during Q2 2024, with a 5-year trough of -$23.5 million in Q3 2022.
- Moreover, its 5-year median value for Income towards Parent Company was -$12.9 million (2025), whereas its average is -$12.6 million.
- As far as peak fluctuations go, ProQR Therapeutics' Income towards Parent Company soared by 7201.08% in 2023, and later plummeted by 40218.09% in 2025.
- ProQR Therapeutics' Income towards Parent Company (Quarter) stood at -$20.8 million in 2021, then surged by 34.92% to -$13.6 million in 2022, then soared by 60.85% to -$5.3 million in 2023, then tumbled by 85.19% to -$9.8 million in 2024, then plummeted by 31.09% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$14.6 million for Q2 2025, and -$11.0 million during Q1 2025.